FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Animals (Basel) / E-Cadherin Immunostaining in Equine Melanocytic Tumors.
Animals : an open access journal from MDPI2023; 13(13); doi: 10.3390/ani13132216

E-Cadherin Immunostaining in Equine Melanocytic Tumors.

Abstract: Melanocytic tumors are an important neoplastic disease in human and veterinary medicine, presenting large differences regarding tumor behavior between species. In horses, these tumors present a prolonged benign behavior, with rare invasiveness and metastases. In humans and small animals, invasion and metastasis have been associated with an Epithelial-Mesenchymal Transition, where the loss of E-cadherin expression plays a key role in tumor progression. This process and the role of E-cadherin have not yet been evaluated in equine melanocytic tumors. This study aimed to assess the immunolabeling of E-cadherin in equine melanocytic tumors and relate this with clinicopathological variables. A total of 72 equine melanocytic tumors were classified as benign and malignant and evaluated by immunohistochemistry for E-cadherin expression. A different pattern of immunostaining was found, contrasting with other species. A total of 69.4% of tumors presented raised immunolabeling of E-cadherin, with 70.7% of melanomas remaining with high expression. The typical loss of immunostaining was not seen in malignant melanomas and no differences were found between benign and malignant melanomas regarding E-cadherin immunostaining. The high immunolabeling of E-cadherin may contribute to the low invasiveness of these tumors, and it is in accordance with the benign behavior of equine melanoma and with the genetic factors associated with its development.
Get Full Text
Publication Date: 2023-07-06 PubMed ID: 37444014PubMed Central: PMC10339947DOI: 10.3390/ani13132216Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article is a study on melanocytic tumors in horses, with focus on the role of E-cadherin in tumor progression. It explains why these tumors in horses bear different characteristics in comparison to humans and other species, presenting a generally benign behavior.

Objectives and Methodology

  • The study aimed to examine the immunolabeling of E-Cadherin in equine melanocytic tumors and explore its correlation with clinicopathological factors.
  • The researchers made use of immunohistochemistry to analyse the expression of E-Cadherin in a total of 72 equine melanocytic tumors, which were divided into benign and malignant types.

Main Findings

  • The study uncovered an atypical immunostaining pattern in equine melanocytic tumors as compared to their counterparts in humans and other animals.
  • The results showed that 69.4% of tumors exhibited heightened immunolabeling of E-cadherin, with about 70.7% of melanomas maintaining a high expression level.

Implications and Conclusions

  • Contrary to expectations based on humans and other animals, a significant loss of immunostaining was not observed in malignant melanomas. There were also no noticeable differences between benign and malignant melanomas in terms of E-cadherin immunostaining.
  • These findings suggest that the high levels of E-cadherin immunostaining may be a contributory factor to the low levels of tumor invasiveness typically observed in horses.
  • This peculiar behavior syncs with the generally benign nature of equine melanoma and offers some understanding of the genetic factors influencing its development.

Cite This Article

APA
Pimenta J, Pires I, Prada J, Cotovio M. (2023). E-Cadherin Immunostaining in Equine Melanocytic Tumors. Animals (Basel), 13(13). https://doi.org/10.3390/ani13132216

Publication

Animals : an open access journal from MDPI
ISSN: 2076-2615
NlmUniqueID: 101635614
Country: Switzerland
Language: English
Volume: 13
Issue: 13

Researcher Affiliations

Pimenta, José
  • Veterinary Sciences Department, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
  • CECAV-Veterinary and Animal Research Center, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
  • Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), 5000-801 Vila Real, Portugal.
Pires, Isabel
  • Veterinary Sciences Department, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
  • CECAV-Veterinary and Animal Research Center, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
  • Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), 5000-801 Vila Real, Portugal.
Prada, Justina
  • Veterinary Sciences Department, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
  • CECAV-Veterinary and Animal Research Center, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
  • Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), 5000-801 Vila Real, Portugal.
Cotovio, Mário
  • Veterinary Sciences Department, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
  • CECAV-Veterinary and Animal Research Center, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
  • Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), 5000-801 Vila Real, Portugal.

Grant Funding

  • UIDP/00772/2020 and LA/P/0059/2020 / Fundação para a Ciência e Tecnologia

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 52 references
  1. Nishiya A.T., Massoco C.O., Felizzola C.R., Perlmann E., Batschinski K., Tedardi M.V., Garcia J.S., Mendonça P.P., Teixeira T.F., Dagli M.L.Z.. Comparative Aspects of Canine Melanoma. Vet. Sci. 2016;3:7.
    doi: 10.3390/vetsci3010007pmc: PMC5644618pubmed: 29056717google scholar: lookup
  2. Wong K., van der Weyden L., Schott C.R., Foote A., Constantino-Casas F., Smith S., Dobson J.M., Murchison E.P., Wu H., Yeh I.. Cross-Species Genomic Landscape Comparison of Human Mucosal Melanoma with Canine Oral and Equine Melanoma. Nat. Commun. 2019;10:353.
    doi: 10.1038/s41467-018-08081-1pmc: PMC6341101pubmed: 30664638google scholar: lookup
  3. Resende L., Moreira J., Prada J., Queiroga F.L., Pires I.. Melanoma—Current Clinical Management and Future Therapeutics. Intech; London, UK: 2015. Current Insights Into Canine Cutaneous Melanocytic Tumours Diagnosis.
  4. van der Weyden L., Patton E.E., Wood G.A., Foote A.K., Brenn T., Arends M.J., Adams D.J.. Cross-Species Models of Human Melanoma. J. Pathol. 2016;238:152–165.
    doi: 10.1002/path.4632pmc: PMC4832391pubmed: 26354726google scholar: lookup
  5. Phillips J.C., Lembcke L.M.. Equine Melanocytic Tumors. Vet. Clin. N. Am. Equine Pract. 2013;29:673–687.
    doi: 10.1016/j.cveq.2013.08.008pubmed: 24267683google scholar: lookup
  6. Moore J.S., Shaw C., Shaw E., Buechner-Maxwell V., Scarratt W.K., Crisman M., Furr M., Robertson J.. Melanoma in Horses: Current Perspectives. Equine Vet. Educ. 2013;25:144–151.
    doi: 10.1111/j.2042-3292.2011.00368.xgoogle scholar: lookup
  7. Teixeira R.B.C., Rendahl A.K., Anderson S.M., Mickelson J.R., Sigler D., Buchanan B.R., Coleman R.J., Mccue M.E.. Coat Color Genotypes and Risk and Severity of Melanoma in Gray Quarter Horses. J. Vet. Intern. Med. 2013;27:1201–1208.
    doi: 10.1111/jvim.12133pubmed: 23875712google scholar: lookup
  8. Rosengren Pielberg G., Golovko A., Sundström E., Curik I., Lennartsson J., Seltenhammer M.H., Druml T., Binns M., Fitzsimmons C., Lindgren G.. A Cis-Acting Regulatory Mutation Causes Premature Hair Graying and Susceptibility to Melanoma in the Horse. Nat. Genet. 2008;40:1004–1009.
    doi: 10.1038/ng.185pubmed: 18641652google scholar: lookup
  9. Albanese V., Newton J.C., Waguespack R.W.. Malignant Melanoma of the Third Eyelid in a Horse. Equine Vet. Educ. 2015;27:e15–e19.
    doi: 10.1111/eve.12012google scholar: lookup
  10. Strauss R.A., Allbaugh R.A., Haynes J., Ben-Shlomo G.. Primary Corneal Malignant Melanoma in a Horse. Equine Vet. Educ. 2019;31:403–409.
    doi: 10.1111/eve.12815google scholar: lookup
  11. Va Metcalfe L., O’brien P.J., Papakonstantinou S., Cahalan S.D., Mcallister H., Duggan V.E.. Malignant Melanoma in a Grey Horse: Case Presentation and Review of Equine Melanoma Treatment Options. Ir. Vet. J. 2013;66:22.
    doi: 10.1186/2046-0481-66-22pmc: PMC4226278pubmed: 24196087google scholar: lookup
  12. Valentine B.A., Calderwood Mays M.B., Cheramie H.S.. Anaplastic Malignant Melanoma of the Tail in Non-Grey Horses. Equine Vet. Educ. 2014;26:156–158.
    doi: 10.1111/eve.12105google scholar: lookup
  13. Cavalleri J.M.V., Mählmann K., Steinig P., Feige K.. Aetiology, Clinical Presentation and Current Treatment Options of Equine Malignant Melanoma—A Review of the Literature. Pferdeheilkunde 2014;30:455–460.
    doi: 10.21836/PEM20140410google scholar: lookup
  14. Hsu M.Y., Meier F.E., Nesbit M., Hsu J.Y., Van Belle P., Elder D.E., Herlyn M.. E-Cadherin Expression in Melanoma Cells Restores Keratinocyte-Mediated Growth Control and down-Regulates Expression of Invasion-Related Adhesion Receptors. Am. J. Pathol. 2000;156:1515–1525.
    doi: 10.1016/S0002-9440(10)65023-7pmc: PMC1876923pubmed: 10793063google scholar: lookup
  15. D’arcy C., Kiel C.. Cell Adhesion Molecules in Normal Skin and Melanoma. Biomolecules 2021;11:1213.
    doi: 10.3390/biom11081213pmc: PMC8391223pubmed: 34439879google scholar: lookup
  16. Eddy K., Shah R., Chen S.. Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. Front. Oncol. 2021;10:626129.
    doi: 10.3389/fonc.2020.626129pmc: PMC7891057pubmed: 33614507google scholar: lookup
  17. Vandyck H.H., Hillen L.M., Bosisio F.M., Van Den Oord J., Zur Hausen A., Winnepenninckx V.. Rethinking the Biology of Metastatic Melanoma: A Holistic Approach. Cancer Metastasis Rev. 2021;40:603–624.
    doi: 10.1007/s10555-021-09960-8pmc: PMC8213587pubmed: 33870460google scholar: lookup
  18. Smart J.A., Oleksak J.E., Hartsough E.J.. Cell Adhesion Molecules in Plasticity and Metastasis. Mol. Cancer Res. 2021;19:25–37.
    doi: 10.1158/1541-7786.MCR-20-0595pmc: PMC7785660pubmed: 33004622google scholar: lookup
  19. Haass N.K., Smalley K.S.M., Li L., Herlyn M.. Adhesion, Migration and Communication in Melanocytes and Melanoma. Pigment. Cell Res. 2005;18:150–159.
    doi: 10.1111/j.1600-0749.2005.00235.xpubmed: 15892711google scholar: lookup
  20. Han J.I., Kim Y., Kim D.Y., Na K.J.. Alteration in E-Cadherin/β-Catenin Expression in Canine Melanotic Tumors. Vet. Pathol. 2013;50:274–280.
    doi: 10.1177/0300985812457792pubmed: 22895538google scholar: lookup
  21. Dane E., Vries T., Morandini R., Ghanem G., Ruiter D., Muijen G.. E Cadherin Expression in Human Melanoma. Melanoma Res. 1996;6:127–131.
    doi: 10.1097/00008390-199604000-00007pubmed: 8791270google scholar: lookup
  22. Silvestri S., Porcellato I., Mechelli L., Menchetti L., Iussich S., De Maria R., Sforna M., Bongiovanni L., Brachelente C.. E-Cadherin Expression in Canine Melanocytic Tumors: Histological, Immunohistochemical, and Survival Analysis. Vet. Pathol. 2020;57:608–619.
    doi: 10.1177/0300985820934385pubmed: 32578507google scholar: lookup
  23. Burandt E., Lübbersmeyer F., Gorbokon N., Büscheck F., Luebke A.M., Menz A., Kluth M., Hube-Magg C., Hinsch A., Höflmayer D.. E-Cadherin Expression in Human Tumors: A Tissue Microarray Study on 10,851 Tumors. Biomark. Res. 2021;9:44.
    doi: 10.1186/s40364-021-00299-4pmc: PMC8180156pubmed: 34090526google scholar: lookup
  24. Pisamai S., Rungsipipat A., Kalpravidh C., Suriyaphol G.. Gene Expression Profiles of Cell Adhesion Molecules, Matrix Metalloproteinases and Their Tissue Inhibitors in Canine Oral Tumors. Res. Vet. Sci. 2017;113:94–100.
    doi: 10.1016/j.rvsc.2017.09.009pubmed: 28918236google scholar: lookup
  25. Pires I., Gomes J., Prada J., Pereira D., Queiroga F.L.. Recent Advances in the Biology, Therapy and Management of Melanoma. InTech; London, UK: 2013. MMP-2 and MMP-9 Expression in Canine Cutaneous Melanocytic Tumours: Evidence of a Relationship with Tumoural Malignancy.
    doi: 10.5772/54878google scholar: lookup
  26. Campagne C., Julé S., Bernex F., Estrada M., Aubin-Houzelstein G., Panthier J.-J., Egidy G.. RACK1, a Clue to the Diagnosis of Cutaneous Melanomas in Horses. BMC Vet. Res. 2012;8:95.
    doi: 10.1186/1746-6148-8-95pmc: PMC3543212pubmed: 22747534google scholar: lookup
  27. Pires I., Queiroga F., Alves A., Silva F., Lopes C.. Decrease of E-Cadherin Expression in Canine Cutaneous Histiocytoma Appears to Be Related to Its Spontaneous Regression. Anticancer Res. 2009;29:2713–2718.
    pubmed: 19596951
  28. Sáez-Ayala M., Montenegro M.F., Sánchez-del-Campo L., Fernández-Pérez M.P., Chazarra S., Freter R., Middleton M., Piñero-Madrona A., Cabezas-Herrera J., Goding C.R.. Directed Phenotype Switching as an Effective Antimelanoma Strategy. Cancer Cell. 2013;24:105–119.
    doi: 10.1016/j.ccr.2013.05.009pubmed: 23792190google scholar: lookup
  29. Pearlman R.L., de Oca M.K.M., Pal H.C., Afaq F.. Potential Therapeutic Targets of Epithelial–Mesenchymal Transition in Melanoma. Cancer Lett. 2017;391:125–140.
    doi: 10.1016/j.canlet.2017.01.029pmc: PMC5371401pubmed: 28131904google scholar: lookup
  30. Kreizenbeck G.M., Berger A.J., Subtil A., Rimm D.L., Gould Rothberg B.E.. Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma. Cancer Epidemiol. Biomark. Prev. 2008;17:949–958.
    doi: 10.1158/1055-9965.EPI-07-2729pmc: PMC3312613pubmed: 18398036google scholar: lookup
  31. Veloso E.S., Gonçalves I.N.N., Silveira T.L., Espirito Santo J.T., Figueiredo L.V., Varaschin M.S., Cassali G.D., Del Puerto H.L., Ferreira E.. ZEB and Snail Expression Indicates Epithelial-Mesenchymal Transition in Canine Melanoma. Res. Vet. Sci. 2020;131:7–14.
    doi: 10.1016/j.rvsc.2020.04.007pubmed: 32278962google scholar: lookup
  32. Armando F., Mazzola F., Ferrari L., Corradi A.. An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?. Vet. Sci. 2023;10:19.
    doi: 10.3390/vetsci10010019pmc: PMC9865109pubmed: 36669020google scholar: lookup
  33. Schmid F., Brodesser D., Reifinger M., Forte S., Semp P., Eberspächer-Schweda M.C., Wolschek M., Brandt S., Kleiter M., Pratscher B.. Canine Oral Primary Melanoma Cells Exhibit Shift to Mesenchymal Phenotype and Phagocytic Behaviour. Vet. Comp. Oncol. 2019;17:211–220.
    doi: 10.1111/vco.12464pubmed: 30719836google scholar: lookup
  34. Loh C.Y., Chai J.Y., Tang T.F., Wong W.F., Sethi G., Shanmugam M.K., Chong P.P., Looi C.Y.. The E-Cadherin and n-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells 2019;8:1118.
    doi: 10.3390/cells8101118pmc: PMC6830116pubmed: 31547193google scholar: lookup
  35. Knottenbelt D.C., Patterson-Kane J.C., Snalune K.L.. Melanocytic Neoplasms. Elsevier; Amsterdam, The Netherlands: 2015; pp. 237–246.
  36. Seltenhammer M.H., Simhofer H., Scherzer S., Zechner P., Curik I., Sölkner J., Brandt S.M., Jansen B., Pehamberger H., Eisenmenger E.. Equine Melanoma in a Population of 296 Grey Lipizzaner Horses. Equine Vet. J. 2003;35:153–157.
    doi: 10.2746/042516403776114234pubmed: 12638791google scholar: lookup
  37. Sundström E., Imsland F., Mikko S., Wade C., Sigurdsson S., Rosengren Pielberg G., Golovko A., Curik I., Seltenhammer M.H., Sölkner J.. Copy Number Expansion of the STX17 Duplication in Melanoma Tissue from Grey Horses. BMC Genom. 2012;13:365.
    doi: 10.1186/1471-2164-13-365pmc: PMC3443021pubmed: 22857264google scholar: lookup
  38. Curik I., Druml T., Seltenhammer M., Sundström E., Pielberg G.R., Andersson L., Sölkner J.. Complex Inheritance of Melanoma and Pigmentation of Coat and Skin in Grey Horses. PLoS Genet. 2013;9:e1003248.
    doi: 10.1371/journal.pgen.1003248pmc: PMC3567150pubmed: 23408897google scholar: lookup
  39. Peres J., Damerell V., Chauhan J., Popovic A., Desprez P.Y., Galibert M.D., Goding C.R., Prince S.. TBX3 Promotes Melanoma Migration by Transcriptional Activation of ID1, Which Prevents Activation of E-Cadherin by MITF. J. Investig. Dermatol. 2021;141:2250–2260.e2.
    doi: 10.1016/j.jid.2021.02.740pubmed: 33744299google scholar: lookup
  40. Hartman M.L., Czyz M.. MITF in Melanoma: Mechanisms behind Its Expression and Activity. Cell. Mol. Life Sci. 2015;72:1249–1260.
    doi: 10.1007/s00018-014-1791-0pmc: PMC4363485pubmed: 25433395google scholar: lookup
  41. Dilshat R., Fock V., Kenny C., Gerritsen I., Lasseur R.M.J., Travnickova J., Eichhoff O., Cerny P., Möller K., Sigurbjörnsdóttir S.. Mitf Reprograms the Extracellular Matrix and Focal Adhesion in Melanoma. eLife 2021;10:e63093.
    doi: 10.7554/eLife.63093pmc: PMC7857731pubmed: 33438577google scholar: lookup
  42. Vachtenheim J., Ondrušová L.. Microphthalmia-Associated Transcription Factor Expression Levels in Melanoma Cells Contribute to Cell Invasion and Proliferation. Exp. Dermatol. 2015;24:481–484.
    doi: 10.1111/exd.12724pubmed: 25866058google scholar: lookup
  43. Joshi S.S., Hornyak T.J.. Cellular Phenotypic Plasticity of Cutaneous Melanoma: A Complex Puzzle. J. Investig. Dermatol. 2020;140:743–745.
    doi: 10.1016/j.jid.2019.11.025pubmed: 32200877google scholar: lookup
  44. Bockhorn M., Jain R.K., Munn L.L.. Active versus Passive Mechanisms in Metastasis: Do Cancer Cells Crawl into Vessels, or Are They Pushed?. Lancet Oncol. 2007;8:444–448.
    doi: 10.1016/S1470-2045(07)70140-7pmc: PMC2712886pubmed: 17466902google scholar: lookup
  45. Bønnelykke-Behrndtz M.L., Steiniche T., Damsgaard T.E., Georgsen J.B., Danielsen A., Bastholt L., Møller H.J., Nørgaard P.H., Schmidt H.. MelanA-Negative Spindle-Cell Associated Melanoma, a Distinct Inflammatory Phenotype Correlated with Dense Infiltration of CD163 Macrophages and Loss of E-Cadherin. Melanoma Res. 2015;25:113–118.
    doi: 10.1097/CMR.0000000000000138pubmed: 25602697google scholar: lookup
  46. Seltenhammer M.H., Heere-Ress E., Brandt S., Druml T., Jansen B., Pehamberger H., Niebauer G.W.. Comparative Histopathology of Grey-Horse-Melanoma and Human Malignant Melanoma. Pigment. Cell Res. 2004;17:674–681.
    doi: 10.1111/j.1600-0749.2004.00192.xpubmed: 15541026google scholar: lookup
  47. Smedley R.C., Spangler W.L., Esplin D.G., Kitchell B.E., Bergman P.J., Ho H.Y., Bergin I.L., Kiupel M.. Prognostic Markers for Canine Melanocytic Neoplasms: A Comparative Review of the Literature and Goals for Future Investigation. Vet. Pathol. 2011;48:54–72.
    doi: 10.1177/0300985810390717pubmed: 21266721google scholar: lookup
  48. Sullins K.E.. Melanocytic Tumours in Horses. Equine Vet. Educ. 2020;32:624–630.
    doi: 10.1111/eve.13159google scholar: lookup
  49. Pilsworth R.C., Knottenbelt D.. Skin Diseases Refresher Melanoma. Equine Vet. Educ. 2006;18:296–340.
  50. Knottenbelt D.C., Patterson-Kane J.C., Snalune K.L.. Tumours of the Skin. Elsevier; Amsterdam, The Netherlands: 2015; pp. 544–584.
  51. Bellenghi M., Puglisi R., Pontecorvi G., De Feo A., Carè A., Mattia G.. Sex and Gender Disparities in Melanoma. Cancers 2020;12:1819.
    doi: 10.3390/cancers12071819pmc: PMC7408637pubmed: 32645881google scholar: lookup
  52. Burden K.. Melanomas and Their Effect on the Grey Horse. Young Sci. J. 2011;4:75.
    doi: 10.4103/0974-6102.92207google scholar: lookup

Citations

This article has been cited 4 times.
  1. Shin JW, Kim Y, Lee SH, Lee SY, Lee JY, Kim CL, Park MR, Ko YG, Chung Y. Identification of TYR gene variants associated with white coat color in Hanwoo cattle using whole-genome sequencing. BMC Genomics 2026 Jan 5;27(1):128.
    doi: 10.1186/s12864-025-12458-0pubmed: 41491788google scholar: lookup
  2. Labelle AL, Gemensky Metzler AM, McMullen RJ Jr, Wiggans KT, Labelle P, Hamor RE. Equine intraocular melanocytic neoplasia. Can Vet J 2024 Oct;65(10):1048-1054.
    pubmed: 39355695
  3. Pimenta J, Prada J, Pires I, Cotovio M. Cyclooxygenase-2 (COX-2) Expression in Equine Melanocytic Tumors. Vet Sci 2024 Feb 7;11(2).
    doi: 10.3390/vetsci11020077pubmed: 38393095google scholar: lookup
  4. Triguinho A, Fontes-Sousa AP, Pimenta J, Cotovio M. Electrocardiographic Reference Values in Clinically Healthy Lusitano Horses. Vet Sci 2023 Aug 10;10(8).
    doi: 10.3390/vetsci10080518pubmed: 37624305google scholar: lookup
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.